Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Platelet Aggregation Clear all
Terminated Phase 4 Interventional Accepts healthy volunteers

Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration

NCT00748371
View directory record Official record
Conditions
Platelet Aggregation
Interventions
aspirin, placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Consumption of Oral Artificial Sweeteners on Platelet Aggregation and Polyol Excretion

NCT04731363
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
xylitol, 30g, erythritol, 30g, xylitol, 5g, glucose, 30g
Dietary Supplement
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Phase 4 Interventional Results available

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

NCT01069003
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo Arm, Thienopyridine Therapy, Surveillance Arm
Drug · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
19 Years and older
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Not applicable Interventional

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

NCT00645918
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
clopidogrel, placebo
Drug
Lead sponsor
Accumetrics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
72
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 22, 2026, 12:51 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

The Effects of Lovaza® in Acute Myocardial Infarction

NCT01155336
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Lovaza®, The placebo contained 1 gram of corn oil in each capsule.
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 22, 2026, 12:51 AM EDT
Recruiting No phase listed Observational

Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders

NCT07083583
View directory record Official record
Conditions
Bleeding Disorders, Iron, Platelet, Bleeding
Interventions
IV Iron (standard of care)
Drug
Lead sponsor
Nicoletta C Machin
Other
Eligibility
15 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Phase 4 Interventional Results available

The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)

NCT02683707
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Removal of Fentanyl from peri-procedural analgesia, Fentanyl, Lidocaine, Midazolam
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Not applicable Interventional Results available

In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients

NCT02081443
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor 180mg, Ticagrelor 90mg
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects

NCT01307657
View directory record Official record
Conditions
Healthy
Interventions
high fat meal
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 22, 2026, 12:51 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Chlorthalidone and HCTZ Impacts on Platelet Activation

NCT02100462
View directory record Official record
Conditions
Hypertension
Interventions
Chlorthalidone 12.5 mg, Hydrochlorothiazide 25 mg, Aspirin 81 mg
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 22, 2026, 12:51 AM EDT
Not listed Phase 2Phase 3 Interventional

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

NCT02889549
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Platelet Function and Safety After IV and Oral Diclofenac, IV Ketorolac and Oral Aspirin in Adult Volunteers

NCT00548678
View directory record Official record
Conditions
Healthy
Interventions
intravenous diclofenac sodium (DIC075V), ketorolac, oral diclofenac (Cataflam), aspirin
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2008 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Assessment of Platelet Reactivity After the Intake of Oleocanthal

NCT03528603
View directory record Official record
Conditions
Platelet Aggregation, Nutritional and Metabolic Disease, Cardiovascular Diseases
Interventions
Oleocanthal-Rich Extra Virgin Olive Oil, Oleocanthal-low Extra Virgin Olive Oil
Other
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 22, 2026, 12:51 AM EDT
Terminated Phase 4 Interventional Results available

Does An Abnormal PFA 100 Predict Bleeding After Renal Biopsy?

NCT00334204
View directory record Official record
Conditions
Kidney Failure, Acute, Kidney Failure, Chronic, Blood Platelet Disorders, Hemorrhage
Interventions
measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy
Device
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 22, 2026, 12:51 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Genetic and Dietary Predictors of Anti-platelet Response

NCT04456608
View directory record Official record
Conditions
Platelet Function
Interventions
Aspirin
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
3
States / cities
Anchorage, Alaska • Missoula, Montana • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects

NCT00368238
View directory record Official record
Conditions
Healthy Subjects
Interventions
Recombinant human erythropoietin alfa (drug), Aspirin (drug), Clopidogrel (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 40 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2006 · Synced Oct 22, 2026, 12:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Aggreguide A-100 ADP Assay Evaluation

NCT02112539
View directory record Official record
Conditions
Platelet Aggregation, ADP Blockers
Interventions
platelet aggregation measurement
Other
Lead sponsor
Aggredyne, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 22, 2026, 12:51 AM EDT
Not listed No phase listed Observational

Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia

NCT03288441
View directory record Official record
Conditions
Hematologic Neoplasms, Thrombocytopenia, Anticoagulants, Platelet Aggregation Inhibitors
Interventions
Hold, Prophylactic dose antithrombotic, Change antithrombotic Drug, Change platelet transfusion threshold, Full dose antithrombotics, Mechanical measures, Intermediate dose antithrombotic
Drug · Biological · Device
Lead sponsor
Maastricht University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

GM03 - Platelet RNA Signatures of Aspirin

NCT05278637
View directory record Official record
Conditions
Platelet Aggregation Inhibitors, Aspirin, Ticagrelor, RNA
Interventions
Aspirin, Ticagrelor
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Oct 22, 2026, 12:51 AM EDT
Not listed No phase listed Observational

Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery

NCT00653601
View directory record Official record
Conditions
Bleeding, Thrombosis
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Pioglitazone on Platelet Function

NCT00861341
View directory record Official record
Conditions
Diabetes, Platelet Function, Healthy
Interventions
Aspirin, Pioglitazone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 22, 2026, 12:51 AM EDT
Completed No phase listed Observational

Platelet Function on Abacavir and Tenofovir

NCT03081572
View directory record Official record
Conditions
Cardiovascular Diseases, Platelet Aggregation, Spontaneous, HIV/AIDS
Interventions
Platelet aggregation
Diagnostic Test
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975
View directory record Official record
Conditions
Stroke, Myocardial Infarctions
Interventions
Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 31, 2015 · Synced Oct 22, 2026, 12:51 AM EDT
Completed Phase 1 Interventional

Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors

NCT01806077
View directory record Official record
Conditions
Vascular Disease, Coronary Artery Disease Risk Factors Multiple
Interventions
PZ-128
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Oct 22, 2026, 12:51 AM EDT